Endoscopic Management of Crohn’s Disease Strictures

Main Article Content

O. Suliman C. Lavery R. Murray TC. Tham


Crohn’s disease is a chronic, progressive inflammatory condition characterised by gastrointestinal tract inflammation and extra-intestinal manifestations.


Some patients may develop stricturing disease, which may either be of inflammatory, fibrotic or post-anastamotic aetiologies.


The management of fibrostenosis is challenging, necessitating preventative strategies and a multidisciplinary approach to its diagnosis and management once established.  Although several treatment options are currently used in the management of strictures, there are currently no targeted anti-fibrotic therapies. Endoscopically, there are several modalities that can be employed in the symptomatic patient including balloon dilatation and stenting.


In this article we will briefly discuss the pathophysiology and investigations with focus centred around endoscopic management of Crohn’s strictures, before suggesting a strategy to employ when approaching these cases.

Keywords: Crohn’s Disease, Endoscopic Management, Endoscopic Management of Crohn’s Disease Strictures

Article Details

How to Cite
SULIMAN, O. et al. Endoscopic Management of Crohn’s Disease Strictures. Medical Research Archives, [S.l.], v. 12, n. 3, mar. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5128>. Date accessed: 13 apr. 2024. doi: https://doi.org/10.18103/mra.v12i3.5128.
Research Articles


1. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19(Suppl A):5A–36A.

2. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777-782. doi:10.1136/gut.49.6.777

3. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8(4):244-250. doi:10.1097/00054725-200207000-00002

4. Papi C, Festa V, Fagnani C, et al. Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis. 2005;37(4):247-253. doi:10.101 6/j.dld.2004.10.012

5. Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology. 2017;152:340–50.

6. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut. 2013; 62(7):1072-1084. doi:10.1136/gutjnl-2012-304353

7. Rieder F, Latella G, Magro F, et al. European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. J Crohns Colitis. 2016;10(8):873-885. doi:10.1093/ecco-jcc/jjw055

8. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255-266. doi: 10.1016/j.gie.2008.02.017

9. Ismail MS, Charabaty A. Management of Crohn's stricture: medical, endoscopic and surgical therapies. Frontline Gastroenterol. 2022;13 (6):524-530. doi:10.1136/flgastro-2021-101827

10. Sleiman J, El Ouali S, Qazi T, et al. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol. 2021;15(4):401-411. doi:10.1080/17 474124.2021.1854732. PMID: 33225766

11. Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020; 6:22. PMID: 32242028.

12. Chen W, Lu C, Hirota C, Iacucci M, Ghosh S, Gui X. Smooth Muscle Hyperplasia/ Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme. J Crohns Colitis. 2017;11(1):92-104. doi:10.1093/ecco-jcc/jjw126.

13. Zhao JF, Ling FM, Li JR, Chen YD, Huang L, Zhu LR. Role of non-inflammatory factors in intestinal fibrosis. J Dig Dis. 2020;21(6):315-318. doi:10.1111/1751-2980.12883.

14. Panés J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34(2):125-145. doi:10.1111/j.1365-2036.2011.04710.

15. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [published correction appears in Gut. 2021 Apr;70(4):1]. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484

16. Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in Crohn's disease. Saudi J Gastroenterol. 2016;22(3):183-191. doi:10.41 03/1319-3767.182455

17. Chang CW, Wong JM, Tung CC, Shih IL, Wang HY, Wei SC. Intestinal stricture in Crohn's disease. Intest Res. 2015;13(1):19-26. doi:10.5217/ir.2015.13.1.19

18. Bruining DH, Zimmermann EM, Loftus EV Jr, et al. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology. 2018; 154 (4):1172-1194. doi:10.1053/j.gastro .2017.11.274

19. Baumgart DC, Le Berre C. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. N Engl J Med. 2021;385(14):1302-1315. doi:10.1056/NEJMra1907607

20. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22. doi:10.1093/ecco-jcc/jjz180

21. El Ouali S, Click B, Holubar SD, Rieder F. Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease. United European Gastroenterol J. 2020;8(3):2 63-270. doi:10.1177/2050640620901960. PM ID: 32213020

22. Bettenworth D, Gustavsson A, Atreja A, et al. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn’s disease. Inflamm Bowel Dis. 2017;23( 1):133-142. doi:10.1097/MIB.0000000000000988

23. Thienpont C, D'Hoore A, Vermeire S, et al. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy [published correction appears in Gut. 2010 Jul;59(7):1007]. Gut. 2010; 59(3):320-324. doi:10.1136/gut.2009.180182

24. Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn's disease. Aliment Pharmacol Ther. 2020; 51(12):1233-1246. doi:10.1111/apt.15750

25. Attar A, Maunoury V, Vahedi K, et al. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012;18(10):1849-1854. doi:10.1002/ibd.22844

26. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn’s and Colitis. 2019;14(2):155–168. doi:10.1093/ecco-jcc/jjz187

27. Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn's disease: report of nine-year follow-up and review of the literature. Inflamm Bowel Dis. 2012; 18(3):506-512. doi: 10.1002/ibd.21739

28. Navaneethan U, Lourdusamy D. Endoscopic Stricturotomy and Strictureplasty. Gastrointest Endosc Clin N Am. 2022;32 (4):687-697. doi:10.1016/j.giec.2022.05.002

29. Shen B, Kochhar G, Navaneethan U, et al. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020;5(4):393-405. doi:10.1016/S2468-1253(19)30366-8

30. Lan N, Shen B. Endoscopic Stricturotomy Versus Balloon Dilation in the Treatment of Anastomotic Strictures in Crohn’s Disease. Inflamm Bowel Dis. 2018;24:897–907. doi:10. 1093/ibd/izx085.